Drug intelligence / Profile preview

ONS-3010

Development stage: Unknown
Lead developer: Outlook Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

ONS-3010 is a biosimilar candidate developed by Oncobiologics Inc. as a biosimilar to **Humira** (adalimumab), a full-length recombinant human IgG1 monoclonal antibody that targets tumor necrosis factor-alpha (TNFα). It is used for treating autoimmune diseases such as rheumatoid arthritis. The drug's mechanism involves TNFα blockade, which significantly reduces TNFα levels and has effects on interleukin-8 (IL-8) release in response to lipopolysaccharide (LPS) and aluminum hydroxide challenges.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on ONS-3010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONS-3010.

Explore the full profile